Business Context and Reporting Period
West Pharmaceutical Services, Inc. designs and manufactures containment, packaging, drug-delivery and contract-manufactured products for biologic, generic, pharmaceutical, diagnostic and medical-device customers. Reportable segments are Proprietary Products and Contract-Manufactured Products. This unaudited Form 10-Q covers the three and nine months ended September 30, 2022, compared with the corresponding 2021 periods.
Key Financial Metrics
| Metric | Q3 2022 | Q3 2021 | 9M 2022 | 9M 2021 |
|---|---|---|---|---|
| Net sales | $686.9 million | $706.5 million | $2,178.2 million | $2,100.8 million |
| Gross profit | $268.0 million | $288.2 million | $874.1 million | $875.2 million |
| Gross margin | 39.0% | 40.8% | 40.1% | 41.7% |
| Operating profit | $186.2 million | $181.4 million | $604.3 million | $568.3 million |
| Operating margin | 27.1% | 25.7% | 27.7% | 27.1% |
| Net income | $120.6 million | $175.6 million | $482.9 million | $514.1 million |
| Diluted EPS | $1.59 | $2.31 | $6.36 | $6.78 |
| Net cash from operating activities | Not separately provided | Not separately provided | $493.2 million | $423.2 million |
- Q3 adjusted net income was $154.1 million, or $2.03 diluted EPS, excluding primarily the pension settlement and related tax effects. Nine-month adjusted net income was $516.2 million, or $6.80 diluted EPS.
- Q3 reported sales declined 2.8%, but increased 4.3% excluding foreign-currency translation. Nine-month sales increased 3.7% as reported and 9.5% excluding currency effects.
- Proprietary Products represented approximately 83% of Q3 sales and grew 5.5% organically; Contract-Manufactured Products declined 1.2% organically. For the nine-month period, organic growth was 12.7% and negative 4.8%, respectively.
- Cash and cash equivalents were $729.0 million at September 30, 2022, compared with $762.6 million at December 31, 2021. Working capital was $1,276.9 million, up from $1,147.9 million.
- Capital expenditures were $189.7 million for the first nine months, compared with $176.9 million in 2021. Free cash flow, as defined by the filing, is not provided.
- Total debt was $209.4 million, including $207.2 million of long-term debt, compared with $253.0 million at year-end 2021. The company had no revolver borrowings and $497.6 million of available capacity, including letters of credit.
- Financing uses included $202.9 million for share repurchases, $43.7 million of long-term debt repayments and $40.0 million of dividends during the first nine months.
Material Changes Versus the Prior Comparable Period
- Reported revenue was pressured by foreign-currency translation, which reduced Q3 sales by approximately $49.8 million and nine-month sales by approximately $121.3 million.
- Gross margin declined 180 basis points in Q3 and 160 basis points for the nine months. Management cited product mix, higher plant spending, production inefficiencies, inflation in raw materials, labor, overhead and transportation, partly offset by price increases and approximately $20.0 million of net one-time fees from COVID-19 supply agreements in Q3.
- Operating profit increased despite lower gross profit, primarily because SG&A declined $25.6 million in Q3 and $33.6 million for the nine months, driven by lower incentive compensation, cost-allocation changes and currency effects.
- Net income and diluted EPS declined substantially because 2022 included a $49.6 million Q3 pension settlement charge, compared with no comparable Q3 charge in 2021. The charge fully settled the U.S. qualified defined benefit pension plan; related tax benefits were approximately $20.0 million in Q3 and $20.3 million for the nine months.
- The 2021 comparable periods benefited from a $20.4 million tax benefit related to prepaid future royalties, which did not recur in 2022. The Q3 effective tax rate rose to 15.0% from 6.6%; the nine-month rate rose to 15.6% from 12.9%.
- Operating cash flow increased $70.0 million year over year, while investing and financing cash usage increased by $17.7 million and $122.2 million, respectively.
Guidance, Outlook, Commentary and Risks
The filing does not provide a clear quantitative full-year revenue or earnings guidance figure. Management stated that cash on hand, operating cash flow and available credit capacity are expected to meet foreseeable liquidity needs.
- Demand for high-value Proprietary Products remained strong, but COVID-19 vaccine and antiviral-related activity declined from prior levels. Contract-manufactured sales were affected by lower diagnostic-device component demand.
- Management is investing to expand manufacturing capacity and meet customer demand. A newly disclosed risk is that the company may be unable to increase capacity or efficiency as planned, potentially causing missed financial targets, production inefficiencies and lower margins from fixed-cost under-absorption.
- Other significant risks include supply-chain interruptions, raw-material and energy costs, inflation, labor availability, customer inventory changes, product mix, regulatory and commercial timing of customer products, reliance on third-party and single-source suppliers, foreign-exchange volatility and competition.
- COVID-19 facilities generally continued operating, but future effects remain uncertain. Through September 30, 2022, the Russia-Ukraine war had not materially affected the company, although management was monitoring raw materials, logistics and European energy availability.
- The company was in compliance with all debt covenants at September 30, 2022. Legal proceedings were described as ordinary-course matters with no expected material adverse effect, and no significant changes to prior disclosed contingencies were reported.
- The company had no material changes in internal control over financial reporting; management concluded disclosure controls were effective.
Important Facts for Investors to Verify
- Whether organic Proprietary Products growth and pricing can offset currency headwinds, inflation and declining COVID-related demand.
- Progress, timing and returns from capacity expansion and capital expenditures.
- Underlying earnings after excluding the $50.8 million nine-month pension settlement charge and other non-GAAP adjustments.
- Sustainability of gross margins, particularly in Proprietary Products, amid product-mix changes and higher labor, transportation and raw-material costs.
- Completion of the 2022 repurchase authorization: 563,334 of 650,000 authorized shares had been repurchased through September 30, 2022.
- Foreign-exchange exposure and the effect of further strengthening of the U.S. dollar on reported sales, earnings and accumulated other comprehensive loss.
- Availability of the $500.0 million revolving credit facility and continued compliance with leverage and interest-coverage covenants.